

Ref: FOI/GS/ID 8312

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

20 July 2023

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Multiple Myeloma.

You asked:

Q1. Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which.

Q2. Of the multiple myeloma patients over the past 6 months, how many were treated with the following:

- a. Belantamab Mafodotin [Blenrep]*
- b. Bortezomib [Velcade] monotherapy or with dexamethasone*
- c. Bortezomib, thalidomide and dexamethasone [VTD]*
- d. Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd)*
- e. Carfilzomib [Kyprolis] and dexamethasone*
- f. Carfilzomib [Kyprolis], Lenalidomide [Revlimid] and dexamethasone*
- g. Daratumumab [Darzalex] monotherapy*
- h. Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd)*
- i. Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd)*
- j. Elranatamab*
- k. Idecabtagene vicleucel [Abecma]*
- l. Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd)*
- m. Ixazomib [Ninlaro], Lenalidomide [Revlimid] and dexamethasone (known as IRd)*
- n. Lenalidomide [Revlimid] monotherapy*

- o. Lenalidomide [Revlimid] and dexamethasone*
- p. Pomalidomide [Imnovid] and dexamethasone*
- q. Selinexor and dexamethasone*
- r. Talquetamab*
- s. Teclistamab [Tecvayli]*
- t. Any other systemic anti-cancer therapy*

Trust response:

1. 151

2.

| | |
|----|----|
| a. | 0 |
| b. | 6 |
| c. | 0 |
| d. | 0 |
| e. | 0 |
| f. | 1 |
| g. | 11 |
| h. | 14 |
| i. | 19 |
| j. | 0 |
| k. | 0 |
| l. | 9 |
| m. | 27 |
| n. | 19 |
| o. | 21 |
| p. | 2 |
| q. | 0 |
| r. | 0 |
| s. | 0 |
| t. | 8 |